Ibrahim Halil Sahin: The Pittsburgh Second Annual GI Cancer Summit – OncoDaily
Ibrahim Halil Sahin: The Pittsburgh Second Annual GI Cancer Summit / cancer, GI cancer, GI Cancer Summit, GI expert, Ibrahim Halil Sahin, OncoDaily, Oncology,
Related Articles
Leading the NHS: proposals to regulate NHS managers
A consultation seeking your views on options for regulating NHS managers, and on the possibility of introducing a professional duty of candour for NHS managers.
Generic weight loss medicines will place new demands on the NHS
Mark Samuels explores how the UK government is leveraging weight loss medications as a strategy to combat obesity and stimulate economic growth, addressing the significant…
Fallen ancient civilizations show us why we must not ignore climate warnings
Archaeology teaches us that we are not immune to extinction.
Are seed oils really as harmful as Robert F. Kennedy Jr. claims?
Rapeseed oil, sunflower oil and other seed oils are perfectly healthy in moderation.
Frontiers | Closing the value-based circle in shared decision-making: a digital framework for informing the shared decision-making process through patient reported outcome and experience measures
BackgroundThe spreading adoption of value-based models of healthcare delivery has incentivized the use of patient-reported outcomes and experience measures (…
Social media in medicine: a personal perspective about opportunities, challenges, and best practice | Published in Clinical Hematology International
By Mohamad Mohty, Bipin Savani. In today’s digital age, social media has become a transformative force, significantly impacting the field of medicine.
The Definitive Guide to How Much Water You Should Drink
Somewhere more than zero and less than 20 liters
How to avoid early mortality in acute promyelocytic leukemia
Abstract. Acute promyelocytic leukemia (APL), a phenotypically and genotypically unique subtype of acute myeloid leukemia, has seen unprecedented advances
Paper: Risk and Patterns of Progression Among Smoldering Myeloma Patients after the Implementation of New Criteria and Modern Imaging
Program: Oral and Poster Abstracts Session: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways:…
Paper: Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome – Long-Term Follow-up of the Ukmra Optimum/Muknine Trial
Program: Oral and Poster Abstracts Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster II Hematology Disease Topics & Pathways: Research, Clinical trials, Combination therapy, Antibody Therapy,…